Recent Company News

• 10:57 PM ET Oct 13, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 05:52 PM ET Oct 21, 2025
  

  CSPC Pharmaceutical Group downgraded to sell from hold at Daiwa (HK$8.92, 0.00)

• 08:06 PM ET Oct 19, 2025
  

  CSPC Pharmaceutical Group receives another breakthrough therapy designation for JSKN003 for treatment of HER2-postive advanced colorectal cancer (HK$8.76, 0.00)

• 08:32 AM ET Oct 18, 2025
  

  Corbus Pharmaceuticals announces data from phase 1/2 clinical study of CRB-701 ($19.32, 0.00)

• 09:47 AM ET Oct 17, 2025
  

  Alphamab Oncology presents first interim analysis results of phase III clinical trial of KN026 (HK$14.39, 0.00)

• 06:23 AM ET Oct 17, 2025
  

  EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Paxlovid ($24.23, 0.00)

• 06:52 AM ET Oct 13, 2025
  

  CSPC Pharmaceutical Group obtains NMPA new drug application for efmedaglutide alfa injection for long-term weight management (HK$9.46, 0.00)

• 06:14 AM ET Oct 09, 2025
  

  FDA approves CSPC Pharmaceutical Group's clinical trial of SYH2070 injection for hypertriglyceridemia or mixed hyperlipidemia (HK$9.40, 0.00)

• 03:23 AM ET Oct 06, 2025
  

  StreetAccount Sector Summary - China Healthcare September Recap